Pfizer Loses U.K. Patent Appeal Over $4.8 Billion Lyrica Drug

Pfizer Inc. lost an appeal in a U.K. patent dispute over Lyrica, one of the company’s top-selling drugs.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.